Trial
NCT01071928
Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma
Phase IIWITHDRAWNEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Hoosier Cancer Research Network
Collaborators
Novartis Pharmaceuticals
Condition
Urothelial Carcinoma
Intervention
Docetaxel
Why stopped
Lack of efficacy of experimental treatment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-08-19